| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genome-Wide Association Study | 126 | 2024 | 1197 | 8.070 |
Why?
|
| Polymorphism, Single Nucleotide | 150 | 2024 | 1892 | 7.480 |
Why?
|
| Genetic Predisposition to Disease | 94 | 2024 | 2099 | 4.260 |
Why?
|
| Genetic Loci | 32 | 2022 | 263 | 2.730 |
Why?
|
| Exome | 23 | 2021 | 200 | 2.650 |
Why?
|
| Cardiovascular Diseases | 38 | 2023 | 1727 | 2.580 |
Why?
|
| Genetic Variation | 43 | 2022 | 876 | 2.230 |
Why?
|
| Diabetes Mellitus, Type 2 | 32 | 2023 | 2097 | 2.010 |
Why?
|
| C-Reactive Protein | 15 | 2020 | 362 | 1.870 |
Why?
|
| Gene Frequency | 42 | 2022 | 481 | 1.860 |
Why?
|
| Phenotype | 62 | 2022 | 2812 | 1.770 |
Why?
|
| Genotype | 55 | 2023 | 1774 | 1.680 |
Why?
|
| Atherosclerosis | 10 | 2023 | 342 | 1.530 |
Why?
|
| Quantitative Trait, Heritable | 16 | 2021 | 117 | 1.500 |
Why?
|
| Coronary Artery Disease | 12 | 2023 | 607 | 1.490 |
Why?
|
| Cholesterol, LDL | 19 | 2022 | 307 | 1.450 |
Why?
|
| Genome, Human | 19 | 2022 | 351 | 1.380 |
Why?
|
| Lipids | 12 | 2022 | 582 | 1.370 |
Why?
|
| Body Mass Index | 31 | 2022 | 1958 | 1.340 |
Why?
|
| Humans | 284 | 2024 | 114756 | 1.290 |
Why?
|
| Stroke | 20 | 2023 | 1019 | 1.290 |
Why?
|
| Obesity | 25 | 2023 | 2513 | 1.240 |
Why?
|
| Quantitative Trait Loci | 17 | 2022 | 307 | 1.240 |
Why?
|
| Genetic Association Studies | 19 | 2022 | 344 | 1.220 |
Why?
|
| Female | 184 | 2024 | 59507 | 1.190 |
Why?
|
| Alleles | 28 | 2022 | 791 | 1.180 |
Why?
|
| Male | 177 | 2024 | 55579 | 1.170 |
Why?
|
| Coronary Disease | 14 | 2023 | 347 | 1.160 |
Why?
|
| Hypertension | 13 | 2022 | 1059 | 1.150 |
Why?
|
| Genetics, Population | 11 | 2023 | 188 | 1.150 |
Why?
|
| Whole Genome Sequencing | 13 | 2022 | 94 | 1.100 |
Why?
|
| Risk Factors | 61 | 2023 | 8627 | 1.020 |
Why?
|
| Middle Aged | 109 | 2023 | 26757 | 1.000 |
Why?
|
| Aged | 91 | 2023 | 19094 | 1.000 |
Why?
|
| Cohort Studies | 51 | 2023 | 4901 | 0.990 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 12 | 2022 | 93 | 0.980 |
Why?
|
| Multifactorial Inheritance | 11 | 2023 | 125 | 0.970 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 9 | 2022 | 916 | 0.920 |
Why?
|
| Homocysteine | 2 | 2018 | 136 | 0.900 |
Why?
|
| Dyslipidemias | 4 | 2021 | 154 | 0.850 |
Why?
|
| Body Height | 7 | 2022 | 180 | 0.840 |
Why?
|
| Renal Insufficiency, Chronic | 6 | 2023 | 486 | 0.810 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 3 | 2019 | 9 | 0.810 |
Why?
|
| Antigens, CD | 3 | 2022 | 443 | 0.790 |
Why?
|
| Mendelian Randomization Analysis | 10 | 2023 | 43 | 0.790 |
Why?
|
| Linkage Disequilibrium | 19 | 2022 | 245 | 0.770 |
Why?
|
| Adult | 94 | 2023 | 30548 | 0.770 |
Why?
|
| Polymorphism, Genetic | 8 | 2016 | 612 | 0.750 |
Why?
|
| Fatty Liver | 2 | 2021 | 213 | 0.750 |
Why?
|
| Potassium | 2 | 2018 | 128 | 0.740 |
Why?
|
| Longitudinal Studies | 26 | 2022 | 2386 | 0.730 |
Why?
|
| Biomarkers | 18 | 2023 | 3416 | 0.690 |
Why?
|
| Models, Genetic | 14 | 2022 | 565 | 0.690 |
Why?
|
| Adiposity | 8 | 2021 | 457 | 0.660 |
Why?
|
| Chromosome Mapping | 12 | 2022 | 489 | 0.640 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 5 | 2019 | 16 | 0.630 |
Why?
|
| Peptidyl-Dipeptidase A | 2 | 2018 | 51 | 0.630 |
Why?
|
| Antihypertensive Agents | 5 | 2020 | 429 | 0.620 |
Why?
|
| Triglycerides | 12 | 2016 | 470 | 0.610 |
Why?
|
| Genetic Markers | 11 | 2021 | 321 | 0.610 |
Why?
|
| Proprotein Convertase 9 | 5 | 2019 | 61 | 0.590 |
Why?
|
| alpha-Globins | 4 | 2022 | 11 | 0.580 |
Why?
|
| Blood Glucose | 10 | 2021 | 1821 | 0.580 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2016 | 368 | 0.570 |
Why?
|
| Fasting | 8 | 2022 | 242 | 0.570 |
Why?
|
| Atrial Fibrillation | 4 | 2023 | 324 | 0.560 |
Why?
|
| Adipose Tissue | 4 | 2020 | 539 | 0.550 |
Why?
|
| Cholesterol, HDL | 10 | 2016 | 184 | 0.550 |
Why?
|
| Hematologic Diseases | 2 | 2016 | 57 | 0.540 |
Why?
|
| Diabetes Mellitus | 7 | 2023 | 904 | 0.540 |
Why?
|
| Lipid Metabolism | 4 | 2021 | 446 | 0.530 |
Why?
|
| Genomics | 9 | 2023 | 639 | 0.530 |
Why?
|
| Blood Pressure | 12 | 2022 | 1530 | 0.530 |
Why?
|
| Chromosomes, Human, Pair 6 | 2 | 2015 | 44 | 0.530 |
Why?
|
| Vestibular Diseases | 1 | 2016 | 22 | 0.520 |
Why?
|
| Haplotypes | 22 | 2022 | 453 | 0.510 |
Why?
|
| Young Adult | 34 | 2020 | 10463 | 0.510 |
Why?
|
| Precision Medicine | 5 | 2022 | 338 | 0.510 |
Why?
|
| Heart Failure | 3 | 2022 | 1952 | 0.510 |
Why?
|
| Ribonucleoproteins | 1 | 2016 | 85 | 0.500 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2015 | 66 | 0.500 |
Why?
|
| Insulin Resistance | 5 | 2021 | 1072 | 0.490 |
Why?
|
| Glomerular Filtration Rate | 10 | 2023 | 604 | 0.490 |
Why?
|
| CD36 Antigens | 2 | 2014 | 37 | 0.480 |
Why?
|
| United States | 37 | 2022 | 12176 | 0.480 |
Why?
|
| Proteins | 7 | 2022 | 912 | 0.480 |
Why?
|
| Intellectual Disability | 1 | 2016 | 129 | 0.480 |
Why?
|
| Face | 1 | 2016 | 168 | 0.470 |
Why?
|
| Abnormalities, Multiple | 1 | 2016 | 177 | 0.470 |
Why?
|
| Mutation, Missense | 6 | 2020 | 295 | 0.470 |
Why?
|
| Sickle Cell Trait | 3 | 2019 | 14 | 0.460 |
Why?
|
| Exploratory Behavior | 2 | 2014 | 82 | 0.460 |
Why?
|
| Aged, 80 and over | 28 | 2021 | 6350 | 0.450 |
Why?
|
| Adolescent | 38 | 2023 | 17808 | 0.440 |
Why?
|
| Sequence Analysis, DNA | 9 | 2018 | 728 | 0.430 |
Why?
|
| Developmental Disabilities | 1 | 2016 | 239 | 0.430 |
Why?
|
| Apolipoprotein L1 | 3 | 2023 | 12 | 0.430 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 2 | 2017 | 80 | 0.430 |
Why?
|
| Prospective Studies | 20 | 2023 | 6217 | 0.430 |
Why?
|
| Kidney | 8 | 2024 | 1184 | 0.420 |
Why?
|
| Genetic Linkage | 7 | 2008 | 297 | 0.410 |
Why?
|
| Serine Endopeptidases | 5 | 2022 | 102 | 0.410 |
Why?
|
| Meta-Analysis as Topic | 5 | 2019 | 161 | 0.400 |
Why?
|
| Receptors, Leptin | 1 | 2012 | 24 | 0.400 |
Why?
|
| Adiponectin | 4 | 2019 | 213 | 0.400 |
Why?
|
| Blood Coagulation | 3 | 2015 | 217 | 0.400 |
Why?
|
| Europe | 7 | 2022 | 336 | 0.400 |
Why?
|
| Asthma | 8 | 2021 | 2032 | 0.380 |
Why?
|
| Case-Control Studies | 22 | 2023 | 3005 | 0.380 |
Why?
|
| Gene Dosage | 2 | 2022 | 134 | 0.380 |
Why?
|
| Factor VIII | 3 | 2020 | 54 | 0.380 |
Why?
|
| Incidence | 13 | 2022 | 2312 | 0.380 |
Why?
|
| Weight Gain | 5 | 2016 | 452 | 0.370 |
Why?
|
| Proteome | 3 | 2023 | 339 | 0.360 |
Why?
|
| Apolipoproteins E | 5 | 2016 | 80 | 0.360 |
Why?
|
| Membrane Proteins | 8 | 2021 | 1022 | 0.360 |
Why?
|
| DNA, Mitochondrial | 2 | 2021 | 182 | 0.350 |
Why?
|
| Carbamoyl-Phosphate Synthase (Ammonia) | 1 | 2010 | 6 | 0.350 |
Why?
|
| Sucrose | 1 | 2010 | 91 | 0.350 |
Why?
|
| Risk Assessment | 12 | 2021 | 2973 | 0.350 |
Why?
|
| Epistasis, Genetic | 4 | 2016 | 67 | 0.350 |
Why?
|
| Fibrinogen | 6 | 2010 | 154 | 0.350 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2010 | 34 | 0.340 |
Why?
|
| Renal Insufficiency | 2 | 2022 | 136 | 0.340 |
Why?
|
| Proportional Hazards Models | 9 | 2021 | 1080 | 0.340 |
Why?
|
| Diabetic Nephropathies | 2 | 2023 | 234 | 0.340 |
Why?
|
| Metabolic Diseases | 2 | 2021 | 99 | 0.330 |
Why?
|
| Pharmacogenomic Variants | 2 | 2019 | 33 | 0.330 |
Why?
|
| Pharmacogenetics | 4 | 2019 | 149 | 0.330 |
Why?
|
| Smoking | 7 | 2022 | 1384 | 0.330 |
Why?
|
| Food Preferences | 1 | 2010 | 108 | 0.330 |
Why?
|
| Erythrocytes | 4 | 2021 | 591 | 0.320 |
Why?
|
| Receptors, Adrenergic, beta-2 | 2 | 2008 | 39 | 0.320 |
Why?
|
| Philippines | 8 | 2013 | 50 | 0.320 |
Why?
|
| Leukocytes | 3 | 2021 | 277 | 0.320 |
Why?
|
| Blood Coagulation Factor Inhibitors | 1 | 2008 | 2 | 0.320 |
Why?
|
| Inflammation | 8 | 2014 | 2481 | 0.310 |
Why?
|
| Electrocardiography | 5 | 2019 | 562 | 0.310 |
Why?
|
| HLA-DRB1 Chains | 2 | 2020 | 98 | 0.310 |
Why?
|
| Taste | 1 | 2010 | 209 | 0.300 |
Why?
|
| Genetic Pleiotropy | 3 | 2022 | 29 | 0.300 |
Why?
|
| Alzheimer Disease | 2 | 2023 | 443 | 0.300 |
Why?
|
| Brain Ischemia | 5 | 2019 | 299 | 0.290 |
Why?
|
| Veterans | 3 | 2023 | 1240 | 0.290 |
Why?
|
| Chromosomes, Human, Pair 5 | 3 | 2018 | 24 | 0.290 |
Why?
|
| Diabetes Complications | 3 | 2021 | 211 | 0.290 |
Why?
|
| Waist-Hip Ratio | 6 | 2019 | 30 | 0.290 |
Why?
|
| Body Fat Distribution | 3 | 2019 | 46 | 0.290 |
Why?
|
| Glucose | 4 | 2022 | 897 | 0.280 |
Why?
|
| Lipopolysaccharide Receptors | 2 | 2021 | 82 | 0.280 |
Why?
|
| Lipoproteins, HDL | 3 | 2017 | 76 | 0.280 |
Why?
|
| Diet | 3 | 2023 | 1080 | 0.280 |
Why?
|
| von Willebrand Factor | 3 | 2020 | 56 | 0.280 |
Why?
|
| Menarche | 3 | 2021 | 49 | 0.280 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2007 | 41 | 0.280 |
Why?
|
| Bayes Theorem | 5 | 2023 | 331 | 0.270 |
Why?
|
| Chromosomes, Human, X | 3 | 2024 | 60 | 0.270 |
Why?
|
| Proteomics | 2 | 2023 | 843 | 0.270 |
Why?
|
| Homeostasis | 2 | 2021 | 575 | 0.270 |
Why?
|
| Liver | 7 | 2021 | 1631 | 0.270 |
Why?
|
| Tunica Intima | 2 | 2006 | 78 | 0.270 |
Why?
|
| Alcoholism | 2 | 2010 | 714 | 0.270 |
Why?
|
| Lipoprotein(a) | 2 | 2017 | 51 | 0.270 |
Why?
|
| Heart Rate | 3 | 2023 | 704 | 0.270 |
Why?
|
| Mississippi | 4 | 2021 | 20 | 0.260 |
Why?
|
| Mitochondria | 2 | 2021 | 751 | 0.260 |
Why?
|
| Fibrinolysis | 1 | 2008 | 158 | 0.260 |
Why?
|
| Blood Platelets | 4 | 2023 | 351 | 0.260 |
Why?
|
| DNA Methylation | 4 | 2022 | 496 | 0.260 |
Why?
|
| Linear Models | 9 | 2021 | 770 | 0.250 |
Why?
|
| Sexual Partners | 1 | 2007 | 161 | 0.250 |
Why?
|
| Aging | 5 | 2017 | 1620 | 0.250 |
Why?
|
| Gene Expression | 4 | 2022 | 1420 | 0.250 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2023 | 501 | 0.250 |
Why?
|
| Lung | 7 | 2022 | 3546 | 0.240 |
Why?
|
| Child | 16 | 2022 | 18352 | 0.240 |
Why?
|
| Epigenesis, Genetic | 4 | 2022 | 521 | 0.240 |
Why?
|
| Codon | 1 | 2005 | 86 | 0.240 |
Why?
|
| Mutation | 7 | 2023 | 3350 | 0.240 |
Why?
|
| Insulin | 6 | 2022 | 2079 | 0.240 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 5 | 2020 | 386 | 0.240 |
Why?
|
| RNA-Binding Proteins | 3 | 2016 | 344 | 0.240 |
Why?
|
| Receptors, LDL | 2 | 2014 | 38 | 0.230 |
Why?
|
| Health Surveys | 4 | 2018 | 443 | 0.230 |
Why?
|
| Iron | 2 | 2017 | 234 | 0.230 |
Why?
|
| Mortality | 2 | 2021 | 288 | 0.230 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2017 | 373 | 0.230 |
Why?
|
| Megakaryocytes | 2 | 2021 | 30 | 0.230 |
Why?
|
| Microbiota | 2 | 2023 | 648 | 0.230 |
Why?
|
| N-Acetylgalactosaminyltransferases | 2 | 2022 | 6 | 0.230 |
Why?
|
| Observational Studies as Topic | 3 | 2019 | 90 | 0.230 |
Why?
|
| Prostatic Neoplasms | 6 | 2014 | 925 | 0.230 |
Why?
|
| Epigenomics | 2 | 2022 | 102 | 0.230 |
Why?
|
| Exercise | 4 | 2018 | 1644 | 0.230 |
Why?
|
| DNA Mutational Analysis | 2 | 2016 | 372 | 0.230 |
Why?
|
| Calcinosis | 2 | 2006 | 242 | 0.220 |
Why?
|
| DNA-Binding Proteins | 4 | 2020 | 1314 | 0.220 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2023 | 29 | 0.220 |
Why?
|
| Open Reading Frames | 2 | 2021 | 116 | 0.220 |
Why?
|
| Hematopoiesis | 3 | 2023 | 172 | 0.220 |
Why?
|
| DNA Copy Number Variations | 2 | 2021 | 158 | 0.220 |
Why?
|
| Carotid Artery Diseases | 2 | 2008 | 57 | 0.220 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2023 | 44 | 0.220 |
Why?
|
| Interleukin-6 | 5 | 2014 | 675 | 0.220 |
Why?
|
| Platelet Count | 5 | 2016 | 81 | 0.220 |
Why?
|
| Myocardial Infarction | 6 | 2019 | 927 | 0.210 |
Why?
|
| Asialoglycoprotein Receptor | 1 | 2022 | 4 | 0.210 |
Why?
|
| Schizophrenia | 4 | 2008 | 415 | 0.210 |
Why?
|
| Risk | 7 | 2014 | 815 | 0.210 |
Why?
|
| Sexual Behavior | 1 | 2007 | 440 | 0.210 |
Why?
|
| Dementia, Vascular | 1 | 2022 | 16 | 0.210 |
Why?
|
| Diabetic Neuropathies | 1 | 2023 | 79 | 0.210 |
Why?
|
| Immunoglobulin E | 2 | 2020 | 316 | 0.210 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2022 | 54 | 0.210 |
Why?
|
| Tunica Media | 1 | 2002 | 35 | 0.200 |
Why?
|
| Sex Factors | 9 | 2021 | 1717 | 0.200 |
Why?
|
| Androgens | 1 | 2024 | 167 | 0.200 |
Why?
|
| Amyloid Neuropathies, Familial | 1 | 2022 | 8 | 0.200 |
Why?
|
| Prealbumin | 1 | 2022 | 22 | 0.200 |
Why?
|
| Age Factors | 11 | 2021 | 2890 | 0.200 |
Why?
|
| Prognosis | 10 | 2022 | 3334 | 0.200 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2022 | 102 | 0.200 |
Why?
|
| Africa | 4 | 2021 | 95 | 0.200 |
Why?
|
| Alcohol Drinking | 3 | 2014 | 654 | 0.200 |
Why?
|
| Heart | 2 | 2016 | 609 | 0.200 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2022 | 96 | 0.200 |
Why?
|
| Exons | 4 | 2016 | 303 | 0.190 |
Why?
|
| Transcription Factors | 3 | 2019 | 1528 | 0.190 |
Why?
|
| Pedigree | 6 | 2013 | 464 | 0.190 |
Why?
|
| Aging, Premature | 1 | 2021 | 11 | 0.190 |
Why?
|
| Platelet Activation | 1 | 2021 | 68 | 0.190 |
Why?
|
| Factor VII | 2 | 2011 | 26 | 0.190 |
Why?
|
| Reproducibility of Results | 10 | 2021 | 2763 | 0.190 |
Why?
|
| E-Selectin | 2 | 2019 | 53 | 0.190 |
Why?
|
| Venous Thromboembolism | 2 | 2022 | 231 | 0.190 |
Why?
|
| Sample Size | 4 | 2023 | 114 | 0.190 |
Why?
|
| Subcutaneous Fat | 1 | 2021 | 70 | 0.180 |
Why?
|
| Intra-Abdominal Fat | 1 | 2021 | 77 | 0.180 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2020 | 29 | 0.180 |
Why?
|
| Genetic Testing | 4 | 2014 | 379 | 0.180 |
Why?
|
| Molecular Epidemiology | 3 | 2022 | 62 | 0.180 |
Why?
|
| Waist Circumference | 3 | 2021 | 122 | 0.180 |
Why?
|
| Genetic Heterogeneity | 3 | 2016 | 49 | 0.180 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 4420 | 0.180 |
Why?
|
| Cholesterol | 4 | 2016 | 368 | 0.170 |
Why?
|
| Chemokine CXCL10 | 1 | 2020 | 34 | 0.170 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 2 | 2013 | 253 | 0.170 |
Why?
|
| Lung Diseases | 2 | 2018 | 696 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 2 | 2 | 2013 | 27 | 0.170 |
Why?
|
| Longevity | 3 | 2017 | 137 | 0.170 |
Why?
|
| Pediatric Obesity | 2 | 2017 | 489 | 0.170 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2019 | 34 | 0.170 |
Why?
|
| Computer Simulation | 7 | 2023 | 878 | 0.170 |
Why?
|
| Diuretics | 1 | 2019 | 66 | 0.170 |
Why?
|
| Ankle Brachial Index | 1 | 2019 | 30 | 0.170 |
Why?
|
| Age Distribution | 2 | 2015 | 339 | 0.170 |
Why?
|
| Warfarin | 2 | 2013 | 135 | 0.170 |
Why?
|
| Sex Distribution | 2 | 2015 | 335 | 0.170 |
Why?
|
| Vital Capacity | 3 | 2018 | 256 | 0.170 |
Why?
|
| Islets of Langerhans | 3 | 2020 | 728 | 0.170 |
Why?
|
| Gene-Environment Interaction | 2 | 2021 | 184 | 0.160 |
Why?
|
| Gout | 1 | 2019 | 37 | 0.160 |
Why?
|
| Family Health | 5 | 2009 | 194 | 0.160 |
Why?
|
| Leptin | 1 | 2020 | 211 | 0.160 |
Why?
|
| Drug Resistance | 1 | 2019 | 158 | 0.160 |
Why?
|
| Hemostasis | 2 | 2009 | 67 | 0.160 |
Why?
|
| Nutrition Surveys | 4 | 2018 | 224 | 0.160 |
Why?
|
| Epidemiologic Studies | 1 | 2019 | 57 | 0.160 |
Why?
|
| Fucosyltransferases | 1 | 2019 | 27 | 0.160 |
Why?
|
| Lipase | 2 | 2021 | 57 | 0.160 |
Why?
|
| Albuminuria | 1 | 2019 | 164 | 0.160 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2018 | 40 | 0.160 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 1 | 2018 | 22 | 0.160 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2020 | 175 | 0.160 |
Why?
|
| Adolescent Health | 2 | 2015 | 37 | 0.160 |
Why?
|
| Uric Acid | 1 | 2019 | 148 | 0.160 |
Why?
|
| Transferrin | 2 | 2017 | 40 | 0.150 |
Why?
|
| Hemoglobin, Sickle | 1 | 2018 | 14 | 0.150 |
Why?
|
| Ferritins | 2 | 2017 | 52 | 0.150 |
Why?
|
| Dihydrotestosterone | 1 | 2018 | 39 | 0.150 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 1521 | 0.150 |
Why?
|
| Antithrombin III | 1 | 2017 | 7 | 0.150 |
Why?
|
| Dermatitis, Atopic | 1 | 2021 | 307 | 0.150 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 5 | 2020 | 22 | 0.150 |
Why?
|
| Anticholesteremic Agents | 1 | 2019 | 128 | 0.150 |
Why?
|
| HLA-DQ alpha-Chains | 1 | 2017 | 14 | 0.150 |
Why?
|
| Factor VIIa | 1 | 2017 | 36 | 0.150 |
Why?
|
| Hemoglobins, Abnormal | 1 | 2017 | 10 | 0.150 |
Why?
|
| Anemia, Iron-Deficiency | 2 | 2017 | 53 | 0.150 |
Why?
|
| Venous Thrombosis | 2 | 2009 | 140 | 0.150 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2015 | 123 | 0.140 |
Why?
|
| Genetic Code | 2 | 2014 | 20 | 0.140 |
Why?
|
| Thromboplastin | 1 | 2017 | 71 | 0.140 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2017 | 24 | 0.140 |
Why?
|
| Inheritance Patterns | 2 | 2019 | 45 | 0.140 |
Why?
|
| Calcium-Binding Proteins | 2 | 2020 | 207 | 0.140 |
Why?
|
| Gene Regulatory Networks | 4 | 2021 | 228 | 0.140 |
Why?
|
| Autonomic Nervous System | 1 | 2017 | 66 | 0.140 |
Why?
|
| Erythropoiesis | 1 | 2016 | 34 | 0.140 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2020 | 610 | 0.140 |
Why?
|
| Base Sequence | 3 | 2016 | 2118 | 0.140 |
Why?
|
| Bronchial Hyperreactivity | 2 | 2008 | 95 | 0.140 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2016 | 29 | 0.140 |
Why?
|
| Tachycardia, Ventricular | 1 | 2018 | 153 | 0.140 |
Why?
|
| Diabetic Angiopathies | 1 | 2019 | 244 | 0.140 |
Why?
|
| Databases, Genetic | 4 | 2021 | 206 | 0.140 |
Why?
|
| Metabolomics | 1 | 2021 | 527 | 0.140 |
Why?
|
| Transcriptome | 1 | 2022 | 727 | 0.140 |
Why?
|
| Interferon-gamma | 1 | 2020 | 722 | 0.140 |
Why?
|
| Sulfonylurea Compounds | 1 | 2016 | 44 | 0.140 |
Why?
|
| Human Migration | 1 | 2016 | 19 | 0.140 |
Why?
|
| Population Surveillance | 2 | 2018 | 392 | 0.140 |
Why?
|
| Kidney Failure, Chronic | 1 | 2021 | 487 | 0.130 |
Why?
|
| Angiopoietins | 1 | 2016 | 12 | 0.130 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein K | 1 | 2016 | 5 | 0.130 |
Why?
|
| Frameshift Mutation | 1 | 2016 | 27 | 0.130 |
Why?
|
| Immune System Diseases | 1 | 2016 | 32 | 0.130 |
Why?
|
| Cross-Sectional Studies | 6 | 2022 | 4409 | 0.130 |
Why?
|
| Anticoagulants | 2 | 2013 | 547 | 0.130 |
Why?
|
| Animals | 14 | 2023 | 31761 | 0.130 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2015 | 743 | 0.130 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2019 | 359 | 0.130 |
Why?
|
| Gene Flow | 1 | 2016 | 77 | 0.130 |
Why?
|
| Factor XII | 1 | 2015 | 5 | 0.130 |
Why?
|
| Inflammation Mediators | 4 | 2016 | 476 | 0.130 |
Why?
|
| Receptors, Interleukin-6 | 2 | 2014 | 34 | 0.130 |
Why?
|
| I-kappa B Kinase | 1 | 2016 | 50 | 0.130 |
Why?
|
| Nervous System Malformations | 1 | 2016 | 34 | 0.130 |
Why?
|
| Palmitoyl-CoA Hydrolase | 1 | 2015 | 1 | 0.130 |
Why?
|
| Receptors, Neurokinin-3 | 1 | 2015 | 6 | 0.130 |
Why?
|
| Odds Ratio | 5 | 2022 | 954 | 0.130 |
Why?
|
| Energy Metabolism | 2 | 2017 | 729 | 0.130 |
Why?
|
| Gallbladder Diseases | 1 | 2015 | 6 | 0.130 |
Why?
|
| Blood Cell Count | 2 | 2016 | 52 | 0.130 |
Why?
|
| Laminin | 1 | 2015 | 69 | 0.120 |
Why?
|
| Defibrillators, Implantable | 1 | 2018 | 286 | 0.120 |
Why?
|
| Motor Activity | 2 | 2013 | 640 | 0.120 |
Why?
|
| Principal Component Analysis | 4 | 2023 | 176 | 0.120 |
Why?
|
| Life Style | 1 | 2017 | 430 | 0.120 |
Why?
|
| Quality Control | 3 | 2021 | 144 | 0.120 |
Why?
|
| Fibroblast Growth Factor 5 | 1 | 2015 | 2 | 0.120 |
Why?
|
| Adipocytes | 1 | 2016 | 188 | 0.120 |
Why?
|
| Plasma Membrane Calcium-Transporting ATPases | 1 | 2015 | 10 | 0.120 |
Why?
|
| Energy Intake | 1 | 2017 | 427 | 0.120 |
Why?
|
| Creatinine | 3 | 2022 | 424 | 0.120 |
Why?
|
| Muscles | 1 | 2016 | 320 | 0.120 |
Why?
|
| Immunoglobulins | 1 | 2015 | 143 | 0.120 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2017 | 278 | 0.120 |
Why?
|
| Body Weight | 3 | 2014 | 869 | 0.120 |
Why?
|
| Mutation Rate | 1 | 2015 | 26 | 0.120 |
Why?
|
| Dopamine beta-Hydroxylase | 1 | 2014 | 12 | 0.120 |
Why?
|
| Apolipoproteins A | 1 | 2014 | 18 | 0.120 |
Why?
|
| Anemia, Sickle Cell | 1 | 2018 | 216 | 0.120 |
Why?
|
| Autoimmunity | 1 | 2020 | 814 | 0.120 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2014 | 10 | 0.120 |
Why?
|
| Alternative Splicing | 1 | 2016 | 188 | 0.120 |
Why?
|
| Vesicular Transport Proteins | 1 | 2015 | 83 | 0.120 |
Why?
|
| Thrombin | 1 | 2015 | 139 | 0.120 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2014 | 16 | 0.120 |
Why?
|
| Apolipoprotein C-III | 1 | 2014 | 13 | 0.120 |
Why?
|
| NAV1.5 Voltage-Gated Sodium Channel | 1 | 2014 | 10 | 0.120 |
Why?
|
| Residence Characteristics | 1 | 2016 | 275 | 0.120 |
Why?
|
| Pleasure | 1 | 2014 | 18 | 0.120 |
Why?
|
| Hypolipidemic Agents | 1 | 2015 | 87 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 8 | 2 | 2019 | 33 | 0.120 |
Why?
|
| Endothelial Protein C Receptor | 2 | 2017 | 5 | 0.120 |
Why?
|
| Forced Expiratory Volume | 5 | 2018 | 476 | 0.120 |
Why?
|
| src-Family Kinases | 1 | 2015 | 88 | 0.120 |
Why?
|
| Taste Perception | 1 | 2014 | 22 | 0.120 |
Why?
|
| Pregnancy | 4 | 2021 | 5525 | 0.120 |
Why?
|
| Sweetening Agents | 1 | 2014 | 37 | 0.110 |
Why?
|
| Gene Expression Regulation | 5 | 2021 | 2321 | 0.110 |
Why?
|
| Respiratory Function Tests | 4 | 2018 | 524 | 0.110 |
Why?
|
| Proprotein Convertases | 1 | 2014 | 14 | 0.110 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2013 | 154 | 0.110 |
Why?
|
| Gene Silencing | 1 | 2014 | 172 | 0.110 |
Why?
|
| Computational Biology | 4 | 2021 | 530 | 0.110 |
Why?
|
| Cholesterol Ester Storage Disease | 1 | 2013 | 1 | 0.110 |
Why?
|
| Sterol Esterase | 1 | 2013 | 2 | 0.110 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2013 | 17 | 0.110 |
Why?
|
| Sepsis | 1 | 2019 | 508 | 0.110 |
Why?
|
| Heart Conduction System | 1 | 2014 | 82 | 0.110 |
Why?
|
| Diabetes, Gestational | 1 | 2017 | 281 | 0.110 |
Why?
|
| Muscle Proteins | 1 | 2015 | 210 | 0.110 |
Why?
|
| Adolescent Behavior | 2 | 2021 | 489 | 0.110 |
Why?
|
| Sympathetic Nervous System | 1 | 2014 | 171 | 0.110 |
Why?
|
| Peripheral Arterial Disease | 1 | 2019 | 380 | 0.110 |
Why?
|
| Repressor Proteins | 1 | 2016 | 367 | 0.110 |
Why?
|
| Selection, Genetic | 2 | 2014 | 243 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 815 | 0.110 |
Why?
|
| Autoantibodies | 1 | 2020 | 1350 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 5 | 2014 | 1133 | 0.110 |
Why?
|
| Alcohol-Related Disorders | 1 | 2014 | 113 | 0.110 |
Why?
|
| Population Groups | 2 | 2021 | 57 | 0.100 |
Why?
|
| Peroxidase | 1 | 2013 | 157 | 0.100 |
Why?
|
| Blood Cells | 1 | 2012 | 38 | 0.100 |
Why?
|
| Hypercholesterolemia | 1 | 2013 | 90 | 0.100 |
Why?
|
| Complement Factor H | 1 | 2013 | 60 | 0.100 |
Why?
|
| Carotid Arteries | 3 | 2011 | 180 | 0.100 |
Why?
|
| Autoantigens | 1 | 2015 | 396 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 347 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2015 | 1218 | 0.100 |
Why?
|
| Interleukin-18 | 1 | 2013 | 219 | 0.100 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2017 | 452 | 0.100 |
Why?
|
| Heterozygote | 3 | 2021 | 251 | 0.100 |
Why?
|
| Apolipoprotein E4 | 1 | 2012 | 32 | 0.100 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 1435 | 0.100 |
Why?
|
| Hemoglobins | 4 | 2019 | 314 | 0.100 |
Why?
|
| Isoenzymes | 2 | 2010 | 285 | 0.100 |
Why?
|
| Pigmentation | 1 | 2012 | 55 | 0.100 |
Why?
|
| Budesonide | 1 | 2012 | 87 | 0.100 |
Why?
|
| Carotid Intima-Media Thickness | 2 | 2023 | 65 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 16 | 3 | 2021 | 30 | 0.100 |
Why?
|
| Vascular Calcification | 1 | 2013 | 107 | 0.100 |
Why?
|
| Conserved Sequence | 1 | 2012 | 218 | 0.100 |
Why?
|
| Mice | 9 | 2023 | 14916 | 0.100 |
Why?
|
| CpG Islands | 2 | 2022 | 117 | 0.100 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2011 | 21 | 0.090 |
Why?
|
| Kininogen, Low-Molecular-Weight | 1 | 2010 | 2 | 0.090 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 592 | 0.090 |
Why?
|
| Kininogens | 1 | 2010 | 4 | 0.090 |
Why?
|
| Signal Transduction | 3 | 2019 | 4521 | 0.090 |
Why?
|
| Kininogen, High-Molecular-Weight | 1 | 2010 | 3 | 0.090 |
Why?
|
| Blood Coagulation Factors | 1 | 2011 | 44 | 0.090 |
Why?
|
| Heart Diseases | 1 | 2014 | 330 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2011 | 67 | 0.090 |
Why?
|
| Metabolic Syndrome | 1 | 2014 | 323 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2019 | 1214 | 0.090 |
Why?
|
| Leukocyte Count | 1 | 2011 | 292 | 0.090 |
Why?
|
| United Kingdom | 2 | 2021 | 226 | 0.090 |
Why?
|
| Endothelium, Vascular | 2 | 2015 | 843 | 0.090 |
Why?
|
| Receptors, Cell Surface | 2 | 2011 | 354 | 0.090 |
Why?
|
| Adenylyl Cyclases | 1 | 2010 | 82 | 0.090 |
Why?
|
| INDEL Mutation | 2 | 2021 | 12 | 0.090 |
Why?
|
| Cyclins | 1 | 2010 | 78 | 0.090 |
Why?
|
| Kidney Function Tests | 2 | 2021 | 140 | 0.090 |
Why?
|
| Cell Differentiation | 1 | 2016 | 1699 | 0.080 |
Why?
|
| Logistic Models | 4 | 2018 | 1843 | 0.080 |
Why?
|
| Cadherins | 1 | 2010 | 176 | 0.080 |
Why?
|
| Cardiovascular System | 1 | 2010 | 125 | 0.080 |
Why?
|
| Molecular Sequence Annotation | 2 | 2021 | 81 | 0.080 |
Why?
|
| Public Health Surveillance | 2 | 2021 | 61 | 0.080 |
Why?
|
| Cytochrome P-450 CYP2C9 | 3 | 2016 | 17 | 0.080 |
Why?
|
| Family | 3 | 2012 | 591 | 0.080 |
Why?
|
| Caspase 10 | 1 | 2008 | 5 | 0.080 |
Why?
|
| Penetrance | 2 | 2021 | 27 | 0.080 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2009 | 88 | 0.080 |
Why?
|
| Caspase 8 | 1 | 2008 | 43 | 0.080 |
Why?
|
| Protein S | 1 | 2008 | 5 | 0.080 |
Why?
|
| HEK293 Cells | 2 | 2021 | 593 | 0.080 |
Why?
|
| Gene Editing | 2 | 2021 | 57 | 0.080 |
Why?
|
| Platelet Aggregation | 2 | 2023 | 94 | 0.080 |
Why?
|
| Coronary Vessels | 2 | 2011 | 227 | 0.080 |
Why?
|
| Protein C | 1 | 2008 | 45 | 0.080 |
Why?
|
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 1 | 2008 | 9 | 0.080 |
Why?
|
| Breast Neoplasms | 2 | 2011 | 1868 | 0.080 |
Why?
|
| RGS Proteins | 1 | 2008 | 12 | 0.080 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2008 | 24 | 0.080 |
Why?
|
| Nerve Tissue Proteins | 2 | 2022 | 529 | 0.080 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2008 | 28 | 0.070 |
Why?
|
| Research Design | 2 | 2014 | 931 | 0.070 |
Why?
|
| Glucocorticoids | 1 | 2012 | 532 | 0.070 |
Why?
|
| Treatment Outcome | 8 | 2019 | 9089 | 0.070 |
Why?
|
| Prevalence | 3 | 2021 | 2249 | 0.070 |
Why?
|
| Time Factors | 5 | 2021 | 6124 | 0.070 |
Why?
|
| BRCA2 Protein | 1 | 2008 | 41 | 0.070 |
Why?
|
| Receptors, Adrenergic, beta-1 | 1 | 2008 | 45 | 0.070 |
Why?
|
| BRCA1 Protein | 1 | 2008 | 56 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 664 | 0.070 |
Why?
|
| Mothers | 2 | 2010 | 651 | 0.070 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2008 | 83 | 0.070 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2008 | 108 | 0.070 |
Why?
|
| Socioeconomic Factors | 3 | 2018 | 1078 | 0.070 |
Why?
|
| Machine Learning | 2 | 2022 | 318 | 0.070 |
Why?
|
| Drosophila | 2 | 2019 | 133 | 0.070 |
Why?
|
| Rectal Neoplasms | 1 | 2008 | 121 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 17 | 2 | 2019 | 56 | 0.070 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2006 | 24 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2006 | 22 | 0.070 |
Why?
|
| Down-Regulation | 2 | 2019 | 596 | 0.070 |
Why?
|
| Mixed Function Oxygenases | 1 | 2006 | 36 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2006 | 53 | 0.070 |
Why?
|
| China | 2 | 2018 | 162 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2022 | 1370 | 0.060 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2008 | 287 | 0.060 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2008 | 286 | 0.060 |
Why?
|
| Renin-Angiotensin System | 1 | 2006 | 71 | 0.060 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2020 | 345 | 0.060 |
Why?
|
| Introns | 3 | 2016 | 227 | 0.060 |
Why?
|
| National Longitudinal Study of Adolescent Health | 2 | 2016 | 7 | 0.060 |
Why?
|
| Genotyping Techniques | 2 | 2016 | 69 | 0.060 |
Why?
|
| Models, Statistical | 3 | 2014 | 604 | 0.060 |
Why?
|
| Thrombosis | 1 | 2008 | 297 | 0.060 |
Why?
|
| Prostate-Specific Antigen | 1 | 2006 | 153 | 0.060 |
Why?
|
| Protein Conformation | 2 | 2020 | 811 | 0.060 |
Why?
|
| Estrogen Receptor alpha | 1 | 2006 | 121 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2007 | 399 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2020 | 3248 | 0.060 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2005 | 184 | 0.060 |
Why?
|
| Lupus Nephritis | 1 | 2005 | 52 | 0.060 |
Why?
|
| Receptor, Melanocortin, Type 4 | 2 | 2016 | 11 | 0.060 |
Why?
|
| Cyclophosphamide | 1 | 2005 | 217 | 0.060 |
Why?
|
| Kidney Glomerulus | 1 | 2005 | 100 | 0.060 |
Why?
|
| Tetraspanins | 1 | 2024 | 15 | 0.060 |
Why?
|
| Carcinoma | 1 | 2005 | 198 | 0.060 |
Why?
|
| Apolipoproteins | 1 | 2023 | 36 | 0.060 |
Why?
|
| Interleukin-13 | 1 | 2004 | 122 | 0.060 |
Why?
|
| Receptors, Thrombin | 1 | 2023 | 11 | 0.060 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2004 | 147 | 0.060 |
Why?
|
| Receptor, PAR-1 | 1 | 2023 | 21 | 0.060 |
Why?
|
| Response Elements | 1 | 2024 | 83 | 0.060 |
Why?
|
| Guanine Nucleotide Dissociation Inhibitors | 1 | 2023 | 2 | 0.050 |
Why?
|
| Interleukin-4 | 1 | 2004 | 208 | 0.050 |
Why?
|
| Intermediate Filaments | 1 | 2023 | 46 | 0.050 |
Why?
|
| Clonal Evolution | 1 | 2023 | 27 | 0.050 |
Why?
|
| Neurofilament Proteins | 1 | 2023 | 34 | 0.050 |
Why?
|
| Privacy | 1 | 2023 | 28 | 0.050 |
Why?
|
| Spirometry | 2 | 2014 | 225 | 0.050 |
Why?
|
| Aminopeptidases | 1 | 2023 | 9 | 0.050 |
Why?
|
| Neoplasm Proteins | 2 | 2019 | 385 | 0.050 |
Why?
|
| Apolipoproteins B | 1 | 2003 | 41 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2007 | 477 | 0.050 |
Why?
|
| Algorithms | 3 | 2016 | 1468 | 0.050 |
Why?
|
| Osteoarthritis, Knee | 1 | 2005 | 213 | 0.050 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2014 | 271 | 0.050 |
Why?
|
| Age of Onset | 2 | 2014 | 448 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2002 | 2269 | 0.050 |
Why?
|
| Carotid Artery, Common | 1 | 2002 | 29 | 0.050 |
Why?
|
| North Carolina | 1 | 2002 | 97 | 0.050 |
Why?
|
| Erythrocyte Count | 2 | 2013 | 19 | 0.050 |
Why?
|
| Erythrocyte Indices | 2 | 2013 | 28 | 0.050 |
Why?
|
| Hyperlipidemias | 1 | 2003 | 122 | 0.050 |
Why?
|
| Lod Score | 3 | 2006 | 65 | 0.050 |
Why?
|
| Hospitalization | 2 | 2022 | 1752 | 0.050 |
Why?
|
| Support Vector Machine | 1 | 2021 | 34 | 0.050 |
Why?
|
| Physical Chromosome Mapping | 1 | 2021 | 16 | 0.050 |
Why?
|
| Microfilament Proteins | 2 | 2013 | 127 | 0.050 |
Why?
|
| Infant, Newborn | 3 | 2022 | 5035 | 0.050 |
Why?
|
| Birth Weight | 2 | 2017 | 440 | 0.050 |
Why?
|
| Biological Variation, Population | 1 | 2021 | 19 | 0.050 |
Why?
|
| Ethanol | 1 | 2005 | 548 | 0.050 |
Why?
|
| Causality | 1 | 2021 | 104 | 0.050 |
Why?
|
| Subcutaneous Tissue | 1 | 2021 | 17 | 0.050 |
Why?
|
| Receptors, Immunologic | 1 | 2022 | 201 | 0.050 |
Why?
|
| Diet Surveys | 1 | 2021 | 78 | 0.050 |
Why?
|
| Serum Albumin | 1 | 2022 | 134 | 0.050 |
Why?
|
| Nitric Oxide | 2 | 2022 | 824 | 0.050 |
Why?
|
| Nucleotides | 1 | 2021 | 112 | 0.050 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 36 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2021 | 24 | 0.050 |
Why?
|
| Protein Disulfide-Isomerases | 1 | 2020 | 8 | 0.050 |
Why?
|
| Small Ubiquitin-Related Modifier Proteins | 1 | 2020 | 6 | 0.050 |
Why?
|
| Protein Inhibitors of Activated STAT | 1 | 2020 | 6 | 0.050 |
Why?
|
| Eye Proteins | 1 | 2021 | 71 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2004 | 374 | 0.050 |
Why?
|
| alpha Karyopherins | 1 | 2020 | 13 | 0.050 |
Why?
|
| Xerostomia | 1 | 2000 | 19 | 0.050 |
Why?
|
| Datasets as Topic | 1 | 2021 | 98 | 0.050 |
Why?
|
| Tripartite Motif Proteins | 1 | 2020 | 30 | 0.050 |
Why?
|
| Vitamin K Epoxide Reductases | 2 | 2013 | 11 | 0.040 |
Why?
|
| Dioxygenases | 1 | 2020 | 25 | 0.040 |
Why?
|
| Nurse-Patient Relations | 1 | 2001 | 43 | 0.040 |
Why?
|
| Eating | 1 | 2023 | 345 | 0.040 |
Why?
|
| Population Density | 1 | 2021 | 94 | 0.040 |
Why?
|
| Interleukin-7 | 1 | 2020 | 45 | 0.040 |
Why?
|
| International Normalized Ratio | 2 | 2013 | 45 | 0.040 |
Why?
|
| Cell Self Renewal | 1 | 2020 | 49 | 0.040 |
Why?
|
| Genetics | 1 | 2020 | 27 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2021 | 170 | 0.040 |
Why?
|
| Africa, Western | 1 | 2020 | 16 | 0.040 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 2 | 2013 | 41 | 0.040 |
Why?
|
| Emphysema | 1 | 2001 | 107 | 0.040 |
Why?
|
| Dystrophin-Associated Proteins | 1 | 2019 | 3 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2021 | 460 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2004 | 935 | 0.040 |
Why?
|
| Myosin Type V | 1 | 2019 | 9 | 0.040 |
Why?
|
| Pneumonectomy | 1 | 2001 | 125 | 0.040 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2019 | 13 | 0.040 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2023 | 400 | 0.040 |
Why?
|
| DNA | 2 | 2022 | 1351 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2020 | 130 | 0.040 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2019 | 26 | 0.040 |
Why?
|
| Western World | 1 | 2019 | 6 | 0.040 |
Why?
|
| Lipoproteins | 2 | 2015 | 160 | 0.040 |
Why?
|
| Cognition | 1 | 2006 | 989 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2022 | 508 | 0.040 |
Why?
|
| Dystrophin | 1 | 2019 | 30 | 0.040 |
Why?
|
| Neuropeptides | 1 | 2019 | 65 | 0.040 |
Why?
|
| Uromodulin | 1 | 2019 | 21 | 0.040 |
Why?
|
| Saliva | 1 | 2000 | 189 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2019 | 20 | 0.040 |
Why?
|
| Child Behavior | 1 | 2021 | 220 | 0.040 |
Why?
|
| Siblings | 2 | 2010 | 222 | 0.040 |
Why?
|
| Physician's Role | 1 | 2001 | 197 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 2019 | 115 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2019 | 268 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2002 | 629 | 0.040 |
Why?
|
| Chromatin | 1 | 2022 | 428 | 0.040 |
Why?
|
| Body Weights and Measures | 1 | 2018 | 34 | 0.040 |
Why?
|
| Decision Trees | 1 | 2018 | 80 | 0.040 |
Why?
|
| Software | 2 | 2014 | 536 | 0.040 |
Why?
|
| Myosin Heavy Chains | 1 | 2019 | 177 | 0.040 |
Why?
|
| Radial Artery | 1 | 1999 | 66 | 0.040 |
Why?
|
| alpha-Thalassemia | 1 | 2018 | 4 | 0.040 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2018 | 48 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2019 | 179 | 0.040 |
Why?
|
| Analysis of Variance | 3 | 2008 | 1226 | 0.040 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2018 | 13 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2022 | 640 | 0.040 |
Why?
|
| Inhalation Exposure | 1 | 2018 | 97 | 0.040 |
Why?
|
| Cytokines | 1 | 2005 | 1843 | 0.040 |
Why?
|
| Drosophila melanogaster | 1 | 2019 | 191 | 0.040 |
Why?
|
| Hand | 1 | 1999 | 134 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 737 | 0.040 |
Why?
|
| Comorbidity | 1 | 2002 | 1449 | 0.040 |
Why?
|
| Nonlinear Dynamics | 1 | 2018 | 83 | 0.040 |
Why?
|
| Coronary Artery Bypass | 1 | 1999 | 198 | 0.040 |
Why?
|
| Breast Feeding | 1 | 2001 | 370 | 0.040 |
Why?
|
| Hemochromatosis | 1 | 2017 | 9 | 0.040 |
Why?
|
| Bronchiectasis | 1 | 2018 | 106 | 0.040 |
Why?
|
| Self Report | 1 | 2021 | 695 | 0.040 |
Why?
|
| Receptors, Transferrin | 1 | 2017 | 22 | 0.040 |
Why?
|
| ADAMTS Proteins | 1 | 2017 | 5 | 0.040 |
Why?
|
| Interleukin-11 Receptor alpha Subunit | 1 | 2017 | 3 | 0.040 |
Why?
|
| Procollagen N-Endopeptidase | 1 | 2017 | 8 | 0.040 |
Why?
|
| NADPH Oxidase 4 | 1 | 2017 | 8 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2022 | 681 | 0.040 |
Why?
|
| Somatomedins | 1 | 2017 | 28 | 0.040 |
Why?
|
| Nutritional Status | 2 | 2010 | 286 | 0.040 |
Why?
|
| Pregnancy-Associated Plasma Protein-A | 1 | 2017 | 14 | 0.040 |
Why?
|
| Education | 1 | 2017 | 95 | 0.040 |
Why?
|
| Multifactor Dimensionality Reduction | 1 | 2016 | 2 | 0.040 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2016 | 30 | 0.030 |
Why?
|
| Syndrome | 1 | 2017 | 334 | 0.030 |
Why?
|
| Hospitals, Community | 1 | 2017 | 45 | 0.030 |
Why?
|
| Hyaluronic Acid | 1 | 1998 | 188 | 0.030 |
Why?
|
| Interferon Regulatory Factors | 1 | 2017 | 29 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2021 | 1128 | 0.030 |
Why?
|
| DNA, Intergenic | 1 | 2016 | 24 | 0.030 |
Why?
|
| Mean Platelet Volume | 1 | 2016 | 3 | 0.030 |
Why?
|
| Transcription Factor AP-2 | 1 | 2016 | 81 | 0.030 |
Why?
|
| NADPH Oxidases | 1 | 2017 | 120 | 0.030 |
Why?
|
| Geographic Information Systems | 1 | 2016 | 37 | 0.030 |
Why?
|
| Anthropometry | 1 | 2017 | 183 | 0.030 |
Why?
|
| Glycosaminoglycans | 1 | 2017 | 79 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2001 | 462 | 0.030 |
Why?
|
| Transportation | 1 | 2016 | 44 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2017 | 107 | 0.030 |
Why?
|
| Pharmacogenomic Testing | 1 | 2016 | 53 | 0.030 |
Why?
|
| Proteolysis | 1 | 2017 | 143 | 0.030 |
Why?
|
| Adipokines | 1 | 2016 | 42 | 0.030 |
Why?
|
| Sexism | 1 | 2016 | 44 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2016 | 4710 | 0.030 |
Why?
|
| Geography | 1 | 2016 | 180 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 2017 | 168 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2013 | 1846 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2018 | 946 | 0.030 |
Why?
|
| Receptors, Androgen | 1 | 2017 | 131 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2016 | 78 | 0.030 |
Why?
|
| Hedgehog Proteins | 1 | 2017 | 173 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 440 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 351 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2020 | 1378 | 0.030 |
Why?
|
| Genes, X-Linked | 1 | 2015 | 16 | 0.030 |
Why?
|
| Health Behavior | 1 | 2021 | 704 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2020 | 799 | 0.030 |
Why?
|
| Microsatellite Repeats | 2 | 2006 | 136 | 0.030 |
Why?
|
| Hypersensitivity | 2 | 2012 | 254 | 0.030 |
Why?
|
| Codon, Nonsense | 1 | 2015 | 37 | 0.030 |
Why?
|
| Brain | 1 | 2007 | 2374 | 0.030 |
Why?
|
| Methionine Adenosyltransferase | 1 | 2015 | 10 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2016 | 152 | 0.030 |
Why?
|
| Circadian Rhythm | 1 | 2018 | 355 | 0.030 |
Why?
|
| Netherlands | 1 | 2015 | 64 | 0.030 |
Why?
|
| Glucose-6-Phosphatase | 1 | 2015 | 31 | 0.030 |
Why?
|
| Apolipoprotein A-V | 1 | 2014 | 3 | 0.030 |
Why?
|
| Glycoproteins | 1 | 2017 | 304 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2017 | 350 | 0.030 |
Why?
|
| Hypogonadism | 1 | 2015 | 75 | 0.030 |
Why?
|
| Allelic Imbalance | 1 | 2014 | 7 | 0.030 |
Why?
|
| Amides | 1 | 2015 | 87 | 0.030 |
Why?
|
| Environment | 1 | 2016 | 336 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2014 | 16 | 0.030 |
Why?
|
| Cytoskeletal Proteins | 1 | 2015 | 145 | 0.030 |
Why?
|
| Philosophy | 1 | 2014 | 6 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2021 | 2196 | 0.030 |
Why?
|
| Endophenotypes | 1 | 2014 | 16 | 0.030 |
Why?
|
| Cell Movement | 1 | 1998 | 867 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2014 | 126 | 0.030 |
Why?
|
| Protective Factors | 1 | 2014 | 87 | 0.030 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2019 | 498 | 0.030 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2015 | 71 | 0.030 |
Why?
|
| Subtilisins | 1 | 2014 | 9 | 0.030 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2014 | 21 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 242 | 0.030 |
Why?
|
| Hyperlipoproteinemia Type III | 1 | 2013 | 3 | 0.030 |
Why?
|
| Heredity | 1 | 2013 | 12 | 0.030 |
Why?
|
| Disease Progression | 1 | 2020 | 2387 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 1796 | 0.030 |
Why?
|
| Membrane Transport Proteins | 1 | 2014 | 138 | 0.030 |
Why?
|
| RNA Interference | 1 | 2015 | 437 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2022 | 12515 | 0.030 |
Why?
|
| Video Games | 1 | 2013 | 21 | 0.030 |
Why?
|
| P-Selectin | 1 | 2013 | 25 | 0.030 |
Why?
|
| Indians, North American | 1 | 2018 | 570 | 0.030 |
Why?
|
| Zebrafish | 1 | 2016 | 411 | 0.030 |
Why?
|
| Homozygote | 1 | 2013 | 187 | 0.030 |
Why?
|
| Hexosyltransferases | 1 | 2012 | 5 | 0.030 |
Why?
|
| Phylogeny | 1 | 2016 | 794 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2019 | 2582 | 0.030 |
Why?
|
| Television | 1 | 2013 | 71 | 0.030 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2014 | 174 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2018 | 1590 | 0.030 |
Why?
|
| Plasma | 1 | 2014 | 210 | 0.030 |
Why?
|
| Hematocrit | 1 | 2012 | 85 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2015 | 382 | 0.030 |
Why?
|
| Neuropsychological Tests | 2 | 2007 | 926 | 0.030 |
Why?
|
| Uncertainty | 1 | 2012 | 96 | 0.020 |
Why?
|
| Skin Tests | 1 | 2012 | 122 | 0.020 |
Why?
|
| Gambia | 1 | 2011 | 12 | 0.020 |
Why?
|
| Nigeria | 1 | 2011 | 14 | 0.020 |
Why?
|
| Genetic Fitness | 1 | 2012 | 55 | 0.020 |
Why?
|
| Duffy Blood-Group System | 1 | 2011 | 5 | 0.020 |
Why?
|
| Chemokine CXCL2 | 1 | 2011 | 37 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2015 | 552 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2011 | 27 | 0.020 |
Why?
|
| GPI-Linked Proteins | 1 | 2011 | 54 | 0.020 |
Why?
|
| Endothelin-1 | 1 | 2013 | 167 | 0.020 |
Why?
|
| Dogs | 1 | 2012 | 334 | 0.020 |
Why?
|
| Reference Values | 2 | 2004 | 742 | 0.020 |
Why?
|
| Interleukin-11 | 1 | 2010 | 9 | 0.020 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2012 | 168 | 0.020 |
Why?
|
| Infant | 2 | 2020 | 7935 | 0.020 |
Why?
|
| Smad3 Protein | 1 | 2010 | 41 | 0.020 |
Why?
|
| Alpha-Globulins | 1 | 2010 | 19 | 0.020 |
Why?
|
| Artifacts | 1 | 2011 | 113 | 0.020 |
Why?
|
| Glucose Tolerance Test | 1 | 2012 | 343 | 0.020 |
Why?
|
| Reproduction | 1 | 2012 | 181 | 0.020 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 2010 | 37 | 0.020 |
Why?
|
| Protein Phosphatase 1 | 1 | 2010 | 28 | 0.020 |
Why?
|
| Biostatistics | 1 | 2010 | 16 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 3039 | 0.020 |
Why?
|
| HLA Antigens | 1 | 2011 | 224 | 0.020 |
Why?
|
| Airway Obstruction | 1 | 2012 | 168 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2011 | 222 | 0.020 |
Why?
|
| DNA Replication | 1 | 2011 | 205 | 0.020 |
Why?
|
| Factor V | 1 | 2009 | 22 | 0.020 |
Why?
|
| Prothrombin | 1 | 2009 | 22 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 1691 | 0.020 |
Why?
|
| Plasminogen | 1 | 2009 | 33 | 0.020 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2009 | 42 | 0.020 |
Why?
|
| Twins | 1 | 2010 | 240 | 0.020 |
Why?
|
| Thrombophilia | 1 | 2009 | 66 | 0.020 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2009 | 40 | 0.020 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2008 | 20 | 0.020 |
Why?
|
| Bronchial Provocation Tests | 1 | 2008 | 53 | 0.020 |
Why?
|
| Educational Status | 1 | 2010 | 412 | 0.020 |
Why?
|
| Puberty | 1 | 2009 | 135 | 0.020 |
Why?
|
| Evolution, Molecular | 1 | 2012 | 437 | 0.020 |
Why?
|
| Pravastatin | 1 | 2008 | 28 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2008 | 38 | 0.020 |
Why?
|
| Simvastatin | 1 | 2008 | 59 | 0.020 |
Why?
|
| Michigan | 1 | 2008 | 96 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2008 | 157 | 0.020 |
Why?
|
| Genetic Counseling | 1 | 2008 | 65 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2014 | 2557 | 0.020 |
Why?
|
| Antioxidants | 1 | 2011 | 530 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2008 | 176 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2020 | 9079 | 0.020 |
Why?
|
| Menopause | 1 | 2009 | 271 | 0.020 |
Why?
|
| Angiotensinogen | 1 | 2006 | 4 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2008 | 305 | 0.020 |
Why?
|
| Potassium Channels, Calcium-Activated | 1 | 2005 | 9 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2005 | 18 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2008 | 482 | 0.020 |
Why?
|
| Weight Lifting | 1 | 2005 | 29 | 0.020 |
Why?
|
| Cause of Death | 1 | 2007 | 362 | 0.020 |
Why?
|
| Calcium | 1 | 2011 | 1103 | 0.020 |
Why?
|
| Basement Membrane | 1 | 2005 | 30 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 994 | 0.020 |
Why?
|
| Antipsychotic Agents | 1 | 2007 | 184 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 2199 | 0.020 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2004 | 44 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2005 | 249 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2008 | 1176 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2005 | 410 | 0.010 |
Why?
|
| Attitude to Health | 1 | 2008 | 406 | 0.010 |
Why?
|
| Overweight | 1 | 2008 | 471 | 0.010 |
Why?
|
| Rats | 1 | 2012 | 4943 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2005 | 356 | 0.010 |
Why?
|
| Postural Balance | 1 | 2005 | 183 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2007 | 1662 | 0.010 |
Why?
|
| Models, Biological | 1 | 2010 | 1630 | 0.010 |
Why?
|
| Walking | 1 | 2005 | 422 | 0.010 |
Why?
|
| Secretory Rate | 1 | 2000 | 16 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2003 | 316 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 2000 | 56 | 0.010 |
Why?
|
| Parotid Gland | 1 | 2000 | 24 | 0.010 |
Why?
|
| Submandibular Gland | 1 | 2000 | 15 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2005 | 647 | 0.010 |
Why?
|
| Cross-Cultural Comparison | 1 | 2001 | 77 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2005 | 1134 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2006 | 1053 | 0.010 |
Why?
|
| Skin Temperature | 1 | 1999 | 16 | 0.010 |
Why?
|
| Transformation, Genetic | 1 | 1998 | 15 | 0.010 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 1999 | 32 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2001 | 317 | 0.010 |
Why?
|
| Genes, ras | 1 | 1998 | 91 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1998 | 133 | 0.010 |
Why?
|
| Hyaluronan Receptors | 1 | 1998 | 91 | 0.010 |
Why?
|
| Blood Pressure Determination | 1 | 1999 | 122 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 1999 | 494 | 0.010 |
Why?
|
| Biological Transport | 1 | 1998 | 372 | 0.010 |
Why?
|
| ROC Curve | 1 | 1999 | 445 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2008 | 1895 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1999 | 424 | 0.010 |
Why?
|
| Motivation | 1 | 2001 | 494 | 0.010 |
Why?
|
| Antibodies | 1 | 1998 | 371 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2001 | 679 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 1998 | 554 | 0.010 |
Why?
|
| Peptides | 1 | 1998 | 848 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2001 | 1183 | 0.010 |
Why?
|